Verrica Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Verrica Pharmaceuticals, Inc.
Keeping Track: US FDA Is Approving JAK Inhibitors Again, Starting With Incyte’s Opzelura; Seagen’s Tivdak Cleared
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Takeda pursues RNA-targeting R&D with Evotec and Anima, looks into liver disease with Genevant. Plus deals involving Kyowa Kirin/Twist, Bright Peak/Ajinimoto & Torii/Verrica.
Keeping Track: Novartis Entresto Wins Expanded Heart Failure Claim; Padcev, Vicineum Seek Bladder Cancer Approvals
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Norwegian biotech Lytix says a licensing deal with Verrica in dermatologic oncology indications gives it commercial validity – and leaves options open in other cancer areas.